Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases using a combination of genomics, machine learning and experimental biology on live human organs. The company uncovers new biological pathways by using advances in 'deep phenotyping', and then studies medicines in human livers.

Ochre Bio brings an extra dimension to drug development data, called deep phenotyping, to study disease and gene systems at a tissue level.

Ochre Bio Executive Team

• Jack Castle, Associate Director, Product Management

• Jack O’ Meara, Co-founder and CEO

• Quin Wills, Co-Founder and CSO

Ochre Bio Board Members

• Alasdair Thong

• Troy Dale